Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer
Young Kwang Chae(Johns Hopkins University), Francis J. Giles(Northwestern University), Wade T. Iams(Centerstone), Andrew A. Davis(Northwestern University), Wungki Park(University of Miami), Nicholas I. Simon(National Cancer Institute), Sarita Agte(Northwestern University), Marcelo Cruz(Alliance for Clinical Trials in Oncology), Alan Pan(Houston Methodist), Victoria Villaflor(Northwestern University), Nisha Mohindra(Fox Chase Cancer Center), Kyunghoon Rhee(Northwestern University), Gilberto Lopes(University of Miami), Keerthi Tamragouri(Northwestern University)
Cited by 125
Related Papers
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484